Download
s13018-021-02297-6.pdf 493,24KB
WeightNameValue
1000 Titel
  • Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty
1000 Autor/in
  1. Oberberg, Stella |
  2. Nottenkämper, Jan |
  3. Heukamp, Matthias |
  4. Krapp, Jan |
  5. Willburger, Roland E. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-27
1000 Erschienen in
1000 Quellenangabe
  • 16(1):163
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13018-021-02297-6 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912510/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Heterotopic ossifications are a common complication after total hip arthroplasty. Low-dose radiation therapy and non-steroidal anti-inflammatory drugs have proven to effectively reduce the rate of heterotopic ossification after total hip arthroplasty. However, a low number of studies describe an equal efficiency of etoricoxib. This work shows first results on the examination of a larger group with 194 subjects to analyze efficiency and rate of side effects under treatment with etoricoxib.!##!Methods!#!Clinical examinations were performed the day before surgery and after at least 12 months. The survey of clinical and functional outcome was done with Harris Hip Score (HHS). Conventional antero-posterior radiographs and second plane in frog leg position were assessed.!##!Results!#!In total, 14 undesirable side effects (7.4%) and only four early terminations of therapy (2.1%) were documented. A complete 1-year follow-up examination including radiographs could be done in 143 subjects (79.4%). Only 28 subjects (19.6%) developed heterotopic ossifications from which 92.9% were classified in type 1 and 7.1% in type 2 using the method described by Brooker. The results do not show correlations with body mass index, extended treatment (more than ten days), or clinical and functional outcome (measured by 'Harris Hip Score'). However, male subjects show a significantly higher rate of heterotopic ossifications.!##!Conclusions!#!The investigations presented in this study confirm a good efficiency of etoricoxib for the prevention of heterotopic ossifications in comparison with classical methods such as radiation or drug therapy and show a low rate of undesirable side effects.
1000 Sacherschließung
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Total hip arthroplasty
lokal Adult [MeSH]
lokal Etoricoxib
lokal Humans [MeSH]
lokal Etoricoxib/therapeutic use [MeSH]
lokal Treatment Outcome [MeSH]
lokal Ossification, Heterotopic/etiology [MeSH]
lokal Middle Aged [MeSH]
lokal Undesirable side effects
lokal Ossification, Heterotopic/prevention
lokal Male [MeSH]
lokal Arthroplasty, Replacement, Hip/adverse effects [MeSH]
lokal Cyclooxygenase 2 Inhibitors/therapeutic use [MeSH]
lokal Research Article
lokal Heterotopic ossification
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3761-1986|https://frl.publisso.de/adhoc/uri/Tm90dGVua8OkbXBlciwgSmFu|https://frl.publisso.de/adhoc/uri/SGV1a2FtcCwgTWF0dGhpYXM=|https://frl.publisso.de/adhoc/uri/S3JhcHAsIEphbg==|https://frl.publisso.de/adhoc/uri/V2lsbGJ1cmdlciwgUm9sYW5kIEUu
1000 Hinweis
  • DeepGreen-ID: 9a9e330407434c0ba4a9a6d478b2960c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463477.rdf
1000 Erstellt am 2023-11-15T18:52:14.488+0100
1000 Erstellt von 322
1000 beschreibt frl:6463477
1000 Zuletzt bearbeitet 2023-11-30T21:44:29.479+0100
1000 Objekt bearb. Thu Nov 30 21:44:29 CET 2023
1000 Vgl. frl:6463477
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463477 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source